STAA

STAAR Surgical Co. 10-Q Summary: Period Ended June 30, 2006

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2006, and the six months ended June 30, 2006, compared to the same periods in 2005. STAAR Surgical Company develops and manufactures visual implants, primarily intraocular lenses (IOLs) for cataract surgery and the Visian ICL for refractive surgery. The company operates globally with significant sales in the United States and Germany. The reporting period reflects the early stages of the U.S. launch of the Visian ICL following FDA approval in December 2005.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 4.7% in the quarter and 1.0% year-to-date compared to 2005. U.S. sales grew 17.7% in the quarter, driven by the Visian ICL launch and improved cataract sales. International sales declined 2.8% in the quarter, largely due to doctor strikes in Germany.
• Expense Increases: Operating expenses rose significantly. Marketing and selling expenses increased 17.2% (quarter) and 10.9% (YTD) due to the U.S. refractive product rollout. Research and development expenses increased 22.0% (quarter) and 27.9% (YTD) due to regulatory costs for the Toric ICL.
• Accounting Changes: The adoption of SFAS 123R (Share-Based Payment) effective December 31, 2005, resulted in a significant increase in stock-based compensation expense ($422,000 for the quarter; $807,000 YTD), contributing to the widened operating loss.
• Product Mix: Refractive sales surged 106.9% in the quarter to $3.45 million, while cataract sales declined 9.1% in the quarter to $10.95 million.

Guidance, Outlook, and Risks

• Strategic Focus: Management is prioritizing the U.S. launch of the Visian ICL and securing FDA approval for the Toric ICL (TICL). The company aims to train 500 surgeons by the end of 2006.
• Liquidity: The company reported a decrease in cash of $4.37 million for the six-month period. Management believes current cash, credit facilities, and option exercises are sufficient to fund operations for the next year, though future profitability is not assured.
• Legal Proceedings: A securities class action lawsuit regarding the Visian ICL approval timeline was preliminarily approved for settlement. The company will pay $3.7 million, with insurance covering most costs except for a $100,000 administrative fee and potential defense costs up to a $500,000 retention.
• Risk Factors: Key risks include the impact of doctor strikes in Germany on cataract sales, competition from multifocal IOLs in the U.S., and the company's history of losses and accumulated deficit of $78.2 million. Continued losses could lead to default on credit facility covenants.

Investor Verification Checklist

• ICL Adoption Rate: Verify the number of surgeons trained and actual U.S. sales volume of the Visian ICL against the target of 500 surgeons by year-end.
• Germany Operations: Monitor the duration and impact of doctor strikes in Germany on the company's largest international market.
• Cash Burn Rate: Assess the sustainability of the current cash burn rate ($5.56 million operating cash outflow YTD) relative to available credit facilities ($3.2 million total available).
• Regulatory Milestones: Track the status of the FDA Pre-Market Approval (PMA) for the Toric ICL (TICL), submitted in April 2006.
• Stock-Based Compensation: Review the impact of SFAS 123R on future earnings, noting $2.7 million of unrecognized compensation cost remaining.